Twin Health
Sensor-driven metabolic modeling aimed at medication reduction
Founded 2018 · Mountain View, CA · Private · Website
Our verdict
The most compelling cost-reduction thesis in this evaluation for a diabetic population. Underwrite it on device-adherence-stratified outcomes and budget for the operational lift.
Scorecard
How it scored
Scored against the published rubric. Weights are fixed before review and identical for every vendor.
Prescriber credentials, titration protocol, comorbidity screening, and off-ramp planning.
Quality of published results: peer review, sample size, control group, and follow-up duration.
Ability to hold net pharmacy spend down: gating, biosimilar strategy, and risk sharing.
Eligibility-level reporting, claims feeds, and whether you can audit the vendor's own numbers.
PBM, carrier, HRIS, and point-solution interoperability without custom engineering.
Time to first appointment, app quality, care-team continuity, and support responsiveness.
Analysis
What we found
Twin Health is the most technically ambitious vendor here, and unusually its ambition points at lowering spend rather than expanding it. Continuous sensor data personalizes nutrition, and the company measures itself on medication elimination — a genuinely rare alignment with what self-insured employers need. Randomized evidence supports the core claims. The practical risks are operational: the model depends on members consistently wearing devices, and outcomes degrade meaningfully when they do not. Integration is also thinner than the price would suggest.
Strengths
- Randomized evidence with medication elimination as a stated endpoint, which almost no vendor attempts
- Continuous sensor data makes clinical decisions auditable rather than self-reported
- Strongest cost-control mechanics in the set — the product is designed to reduce drug spend, not manage it
Limitations
- Device dependency raises operational overhead and creates a real adherence cliff when sensors lapse
- Integration breadth is the weakest among vendors at this price point
- Restricted to a diabetic and prediabetic population, so it cannot anchor a general weight-management strategy
Best for
Employers with concentrated diabetes spend who want a vendor whose success is defined as members needing fewer drugs.
Watch out
Sensor adherence drives everything. Ask for outcomes stratified by device-wear compliance, not blended averages.
The details
Commercial and clinical specifics
The facts you will need to build a comparison grid. Verify each against the vendor's own documentation before contracting.
Pricing
- Model
- Outcomes-based with a significant share of fees at risk
- PMPM range
- $55–$120
- Setup fee
- Includes CGM and connected device provisioning
- Medications included
- No
- Performance guarantees
- Fees tied to A1c reduction and medication-elimination targets
Contract
- Minimum lives
- 1,500
- Term
- 24 months
- Termination notice
- 90 days
Eligibility
- BMI threshold
- Type 2 diabetes or prediabetes required
- Prior authorization
- No
- Step therapy
- Yes
- Comorbidity required
- Yes
Clinical model
- Prescribes
- Yes
- Care team
- Physicians, Endocrinology consultants, Health coaches, Registered dietitians
- Titration protocol
- Continuous sensor data drives individualized nutrition before any medication escalation
- Off-ramp
- Medication elimination is the explicit primary endpoint
- Formulary
- Metformin, Semaglutide (escalation only), Tirzepatide (escalation only), Insulin (reduction focus), SGLT2 inhibitors
Outcomes evidence
- Headline claim
- Company-reported HbA1c reduction and diabetes medication discontinuation from its whole-body digital twin programme
- Evidence level
- Vendor-reportedMarketing figure with no published methodology. Treat as a claim, not a result.
- Sample size
- Not verified in a citation we could confirm
- Follow-up
- Not verified
Sources
- Twin HealthWe could not locate and confirm a specific peer-reviewed citation for Twin Health's own programme during this review. Digital-twin diabetes trials exist in the literature, but we do not attribute them to this vendor without a confirmed reference. Rated vendor-reported until a citation is verified.
Outcomes verified 2026-09-19. Pricing and contract figures on this page are category planning benchmarks, not vendor quotes — see methodology.
Integrations
- PBMs
- CVS Caremark, Express Scripts
- Carriers
- Aetna, Cigna
- HRIS
- Workday, ADP
- Eligibility file
- Flat file, monthly cadence
Formulary
Twin Health by medication
How a vendor positions each molecule reveals more about its cost discipline than any single score. First-line means an eligible member can start immediately; escalation means a documented lower-cost trial comes first.
Twin Health Reviews Semaglutide
GLP-1 receptor agonist
Escalation only, and reached rarely by design. Continuous sensor data drives individualized nutrition first, and Twin's fee structure is tied to medication elimination — so initiating here works against its own economics.
Twin Health Reviews Tirzepatide
Dual GIP/GLP-1 receptor agonist
The last rung, used sparingly. As with semaglutide, Twin's outcomes-based fees are measured against medication reduction, making sustained tirzepatide use a commercial negative for the vendor.
Twin Health Reviews Metformin
Biguanide
A first-line agent that Twin actively works to deprescribe as sensor-guided nutritional response improves. Elimination, not maintenance, is the stated endpoint.
Alternatives
Others in metabolic specialist
Same category, so these are genuine substitutes rather than different products at different prices.
Nutrition-first diabetes and obesity reversal with explicit deprescribing goals
- PMPM benchmark
- $40–$95
- Minimum lives
- 2,000
Virtual cardiometabolic clinic with bundled labs and pharmacy
- PMPM benchmark
- $34–$72
- Minimum lives
- 500